🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Windtree Therapeutics Inc (WINT)

NASDAQ
Currency in USD
0.349
-0.003(-0.77%)
Real-time Data
WINT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
Fair Value
Day's Range
0.3300.360
52 wk Range
0.33014.749
Key Statistics
Edit
Prev. Close
0.352
Open
0.359
Day's Range
0.33-0.36
52 wk Range
0.33-14.749
Volume
375.59K
Average Volume (3m)
1.77M
1-Year Change
-97.36%
Book Value / Share
2.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WINT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Compare WINT to Peers and Sector

Metrics to compare
WINT
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.6x−0.6x
PEG Ratio
0.000.130.00
Price/Book
0.7x2.4x2.6x
Price / LTM Sales
-23.7x3.2x
Upside (Analyst Target)
-113.0%40.6%
Fair Value Upside
Unlock−2.4%7.1%Unlock

Analysts' Recommendations

0 Buy
1 Hold
0 Sell
Ratings:
0 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

People Also Watch

0.316
VRPX
+1.90%
0.451
FOXO
-7.56%
0.418
MTEM
-1.90%
0.5831
TCBP
-0.34%
0.0768
TFFP
-52.80%

FAQ

What Is the Windtree Therapeutics (WINT) Stock Price Today?

The Windtree Therapeutics stock price today is 0.349

What Stock Exchange Does Windtree Therapeutics Trade On?

Windtree Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Windtree Therapeutics?

The stock symbol for Windtree Therapeutics is "WINT."

What Is the Windtree Therapeutics Market Cap?

As of today, Windtree Therapeutics market cap is 3.09M.

What is Windtree Therapeutics Earnings Per Share?

The Windtree Therapeutics EPS is -19.21.

From a Technical Analysis Perspective, Is WINT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.